Asish Ghosh

Dr. Asish Ghosh

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2016 in Leukemia
Verified
Journal Article
Open access
PDF file
JBJ Boysen
J Boysen
MNM Nelson
M Nelson
GMG Magzoub
G Magzoub
GMGuru Maiti
Guru Maiti
SSS Sinha
S Sinha
AGAsish Ghosh
Asish Ghosh
Previously, we reported that B-cell chronic lymphocytic leukemia (CLL) patients contained elevated levels of microvesicles (MVs). However, given the quiescent nature of CLL B-cells and the relative indolence of the disease, the dynamics of MV generation and their unique phenotypes are not clearly defined. In this study, we find that CLL B-cells generate MVs spontaneously and can be further induced by B-cell receptor-ligation. Most interestingly, CLL B-cells predominantly generate CD52+ MVs, but not CD19+ MVs in vitro, suggesting preferential usage of CD52 into leukemic-MVs and that the CLL plasma MV phenotypes corroborate well with the in vitro findings. Importantly, we detected increased accumulation of CD52+ MVs in previously untreated CLL patients with progressive disease. Finally, sequential studies on MVs in pre- and post-therapy CLL patients demonstrate that although the plasma CD52+ MV levels drop significantly after therapy in most and remain at low levels in some patients, a trend of increased accumulation of CD52+ MVs was detected in majority of post-therapy CLL patients (25 of 33). In total, this study emphasizes that dynamic accumulation of CD52+ MVs in plasma can be used to study CLL progression and may be a useful biomarker for patients as they progress and require therapy.

17 May 2021 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
GMGuru Maiti
Guru Maiti
SSSutapa Sinha
Sutapa Sinha
HMHasan Mahmud
Hasan Mahmud
JBJustin Boysen
Justin Boysen
MMMariana T. Mendez
Mariana T. Mendez
AGAsish Ghosh
Asish Ghosh
Mitochondrial metabolism is the key source for abundant ROS in chronic lymphocytic leukemia (CLL) cells. Here, we detected significantly lower superoxide anion (O2−) levels with increased accumulation of hydrogen peroxide (H2O2) in CLL cells vs. normal B-cells. Further analysis indicated that mitochondrial superoxide dismutase (SOD)2, which converts O2− into H2O2 remained deacetylated in CLL cells due to SIRT3 overexpression resulting its constitutive activation. In addition, catalase expression was also reduced in CLL cells suggesting impairment of H2O2-conversion into water and O2 which may cause H2O2-accumulation. Importantly, we identified two CpG-islands in the catalase promoter and discovered that while the distal CpG-island (−3619 to −3765) remained methylated in both normal B-cells and CLL cells, variable degrees of methylation were discernible in the proximal CpG-island (−174 to −332) only in CLL cells. Finally, treatment of CLL cells with a demethylating agent increased catalase mRNA levels. Functionally, ROS accumulation in CLL cells activated the AXL survival axis while upregulated SIRT3, suggesting that CLL cells rapidly remove highly reactive O2− to avoid its cytotoxic effect but maintain increased H2O2-level to promote cell survival. Therefore, abrogation of aberrantly activated cell survival pathways using antioxidants can be an effective intervention in CLL therapy in combination with conventional agents.

24 November 2015 in Leukemia
Verified
Journal Article
Closed access
PDF file
SSS Sinha
S Sinha
JBJ Boysen
J Boysen
MNM Nelson
M Nelson
SWS L Warner
S L Warner
DBD Bearss
D Bearss
AGAsish Ghosh
Asish Ghosh

14 May 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
MMMurali K. Mamidi
Murali K. Mamidi
HMHasan Mahmud
Hasan Mahmud
GMGuru Maiti
Guru Maiti
MMMariana T. Mendez
Mariana T. Mendez
SFStacey M. Fernandes
Stacey M. Fernandes
AGAsish Ghosh
Asish Ghosh

2 June 2020 in Oncotarget
Verified
Journal Article
Open access
PDF file
HMHasan Mahmud
Hasan Mahmud
MMMariana Mendez
Mariana Mendez
BMBedabrata Mukhopadhyay
Bedabrata Mukhopadhyay
JHJennifer Holter-Chakrabarty
Jennifer Holter-Chakrabarty
AGAsish Ghosh
Asish Ghosh
Https://doi.org/10.18632/oncotarget.27409 Hasan Mahmud, Mariana Mendez, Bedabrata Mukhopadhyay, Jennifer Holter-Chakrabarty, Asish K. Ghosh

5 December 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
MMMurali K. Mamidi
Murali K. Mamidi
SSSutapa Sinha
Sutapa Sinha
MMMariana T. Mendez
Mariana T. Mendez
TSTapojyoti Sanyal
Tapojyoti Sanyal
HMHasan Mahmud
Hasan Mahmud
AGAsish Ghosh
Asish Ghosh
Purpose: Although the B-cell receptor (BCR) signal plays a critical role in chronic lymphocytic leukemia (CLL) cell survival and a target of current therapies (ibrutinib targets Bruton’s tyrosine kinase; idelalisib targets PI3Kδ), contribution of the cytokine-driven JAK2 pathway to the “CLL cell-survival signaling network” is largely undefined. Experimental Design: Patients with CLL were enrolled to investigate expression/activation of JAK2 and acylglycerol kinase (AGK), and their functional implication in primary CLL cell survival. A series of biochemical and molecular biology assays were employed to uncover the underlying mechanism. Results: We detected that compared with normal B cells, CLL cells aberrantly express constitutively active JAK2. Mechanistically, HSP90 forms a chaperoning complex with JAK2, resulting in its aberrant accumulation in CLL cells. We also discovered aberrant upregulation of a novel mitochondrial lipid kinase, AGK, which remains complexed with HSP90 in CLL cells activating JAK2. Although AGK is typically mitochondrial, we detected its nuclear localization in association with JAK2 in some CLL cells. Functionally, JAK2 phosphorylates its noncanonical substrate, histone H3(Y41), but not STAT3, activating transcription of diverse sets of genes in a patient-specific manner. Additionally, JAK2 activates the BCR signal in CLL cells via LYN/Bruton’s tyrosine kinase axis. Targeted inhibition of JAK2 as monotherapy, or in combination with the BCR inhibitors or venetoclax (a BCL2 inhibitor), induced apoptosis synergistically in CLL cells. Conclusions: These findings suggest that aberrantly expressed AGK activates JAK2, independent of cytokine, leading to activation of diverse sets of gene transcription in CLL cells. Combined targeting of JAK2 and BCR signals or BCL2 may be effective in some patients with CLL.